Stock Symbol:

CADX

Company Name:

Cadence Pharmaceuticals, Inc.

Company Description:

Cadence Pharmaceuticals, Inc., a development stage company, focuses on in-licensing, developing, and commercializing product candidates principally for use in the hospital setting in the United States and Canada. It holds rights to Ofirmev, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The company in-licensed rights to Ofirmev from Bristol-Myers Squibb Company, which sells this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan.

Investment Sector:

Biotechnology and Drugs

Predicted Split Months:

F-M-A-N

Stock Exchange:

NASDAQ

Predicted Split Price:

$18.00

Predicted Split Ratio:

5 for 4

5 Day Performance After Split:

3.3%

Prior Stock Splits:

0

Stock Split History:

None

Split Predictions Are Based Upon Historical Stock Market Data And Sector Trends. This Data Is For Educational Purposes Only.